This conversation covers some of the other major drug development stories from the EASL Congress 2024, with special focus on denifenstat, ION-224 and TAK-227, plus a look at the SPECIAL study on bariatric surgery and cirrhosis.
EASL Secretary General Aleksander Krag offers his vision for the EASL Congress 2024, after which Hannes Hagstrom shared some impressions.
From INCBCN 2023: Last year’s Barcelona context took a “deep dive” into NITs by exploring some early findings from the NAIL-NIT consortium.
This conversation focuses largely on system preparedness and ways to improve scanners and other screening devices. One key point: this becomes more feasible now that Rezdiffra has been approved.
Our introduction to Maja Thiele includes not only her academic background and interests, but also a first-time “One Thing…” answer and her role in LiverAIM, the largest randomized control trial ever envisioned in SLD.
SLD Think Tank 2023 co-chairs Jörn Schattenberg and Jeff Lazarus and participants Maja Thiele and Mike Betel join Louise Campbell and Roger Green to discuss high points of the recent Barcelona meting.
Louise Campbell and Roger Green interview Stephen Harrison as part of our year-end series for 2022, our last individual interview with Stephen.
This week’s vault episode looks back to last September, when Laurent Castera joined the Surfers to discuss different roles that NITs can play in MASH drug development and patient assessment.
This final conversation about MASH drug development includes continued discussion of combination therapies and a discussion on NITs’ vital role in speeding the process and making it more efficient.
The conversation comes from the first time we discussed MASEF on the podcast. Lead author Mazen Noureddin joined the Surfers to discuss his paper and the potential for this test.
